{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T14:04:03Z","timestamp":1769868243579,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ejogrb.2016.02.030","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T13:11:51Z","timestamp":1456665111000},"page":"63-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The efficacy and tolerability of mirabegron in a non-trial clinical setting"],"prefix":"10.1016","volume":"200","author":[{"given":"Aswini","family":"Balachandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Duckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejogrb.2016.02.030_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurol Urodynam"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0095","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2010.04.022","article-title":"Updated systematic review and meta-analysis of the comparative data on colposuspensions, pubovaginal slings and mid-urethral tapes in the surgical treatment of female stress urinary incontinence","volume":"58","author":"Novara","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","article-title":"An international Urogynecological Association\/International Continence Society (ICS) joint report on the terminology for pelvic floor dysfunction","volume":"21","author":"Haylen","year":"2010","journal-title":"Int Urogynecol J"},{"issue":"3","key":"10.1016\/j.ejogrb.2016.02.030_bib0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","article-title":"The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis","volume":"54","author":"Chapple","year":"2008","journal-title":"Eur Urol"},{"issue":"2 Suppl.","key":"10.1016\/j.ejogrb.2016.02.030_bib0110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.urology.2006.05.043","article-title":"The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis","volume":"68","author":"Khullar","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0115","first-page":"713","article-title":"Mirabegron a \u03b23-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder","volume":"13","author":"Tyagi","year":"2010","journal-title":"Drug"},{"issue":"8","key":"10.1016\/j.ejogrb.2016.02.030_bib0120","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/nau.22373","article-title":"A proof-of-concept study: mirabegron, a new therapy for overactive bladder","volume":"32","author":"Chapple","year":"2013","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"10.1016\/j.ejogrb.2016.02.030_bib0125","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"issue":"5","key":"10.1016\/j.ejogrb.2016.02.030_bib0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1471-0528.2007.01288.x","article-title":"Tolerability and efficacy of duloxetine in a nontrial situation","volume":"114","author":"Duckett","year":"2007","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.ejogrb.2016.02.030_bib0135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/01443610801912931","article-title":"The treatment of urinary incontinence with Duloxetine","volume":"28","author":"Basu","year":"2008","journal-title":"J Obstet Gynaecol"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0140","first-page":"25","article-title":"Update on duloxetine for the management of stress urinary incontinence","volume":"4","author":"Basu","year":"2009","journal-title":"Clin Interv Aging"},{"issue":"2","key":"10.1016\/j.ejogrb.2016.02.030_bib0145","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1471-0528.12069","article-title":"Validation of the patients global impression scales for use in detrusor overactivity: secondary analysis of the RELAX study","volume":"120","author":"Tincello","year":"2013","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.ejogrb.2016.02.030_bib0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ejogrb.2016.02.030_bib0155","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.ejogrb.2016.02.030_bib0160","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/nau.21028","article-title":"Urinary Incontinence Treatment Network (UITN). Minimum important difference for validated instruments inwomen with urge incontinence","volume":"30","author":"Dyer","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0165","article-title":"Efficacy of the \u03b23-adrenoceptor agonists mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomized phase 3 trials","author":"Chapple","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejogrb.2016.02.030_bib0170","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, Phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516300689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211516300689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T21:24:23Z","timestamp":1769808263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211516300689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":17,"alternative-id":["S0301211516300689"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.02.030","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and tolerability of mirabegron in a non-trial clinical setting","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2016.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}